Obsessive-compulsive Disorder
Conditions
Keywords
OCD, Obsessive-Compulsive Disorder, OCD treatment
Brief summary
A 12-week program to examine the effectiveness of topiramate in adjunctive treatment for adults with obsessive-compulsive disorder and who are currently on serotonin reuptake inhibitor medications (ages 18-65).
Detailed description
The Compulsive, Impulsive and Anxiety Disorders Program at the Mount Sinai School of Medicine is conducting a study of Topiramate (Topamax) added to an SSRI for the management of treatment-resistant Obsessive-Compulsive Disorder. The purpose of the study is to evaluate the safety and efficacy of Topiramate versus placebo added to a selective serotonin reuptake inhibitor (SRI) in patients with treatment resistant OCD. The program is 12 weeks in duration and involves regular visits with a psychiatrist as well as complete psychiatric and medical evaluations. Treatment and medication for the study will be provided free of charge.Participants must be between the ages of 18 and 65 and have an onset of OCD at least 1 year prior to screening. In addition, participants must be taking a clinically effective dose of an SSRI for at least 3 months and must maintain their current dose throughout the study. Participants must not have a primary OCD symptom of hoarding.
Interventions
DRUGtopiramate
Sponsors
Ortho-McNeil Pharmaceutical
Montefiore Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Males and Females 18-65 years of age diagnosed with OCD and currently taking SSRI medication(s)
Exclusion criteria
major medical disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and efficacy of adjunctive topiramate vs. placebo in the treatment of OCD | — |
Countries
United States
Outcome results
None listed